Can we help?

call us on +44 (0)131 4456077
or email

share this print page

Investor relations

Bespoke solutions from clinical trial to launch

Investor relations

News


16/05/2012 Angel signs new contract with ReNeuron
16/05/2012 Cell Manufacturing Contract
15/05/2012 Angel Biomedical Ltd announces supply agreement
10/05/2012 Acquisition of assets
26/04/2012 Holding(s) in Company
17/04/2012 Angel and TransGenRx Inc. sign contract
13/04/2012 Result of EGM
26/03/2012 Update on Cramlington
19/03/2012 Notice of EGM and Proposed Placing
05/03/2012 Appointment of acting CEO
02/03/2012 Directorate Change
27/02/2012 Grant of Share Options
06/02/2012 Contracts with Materia Medica
16/01/2012 Holding(s) in Company
10/01/2012 Trading Update
22/12/2011 Placing
16/12/2011 Framework Agreement with TransGenRx Inc.
07/12/2011 UK Government Life Sciences Strategy
05/12/2011 Appointment of Commercial Director
17/10/2011 Intent to establish joint venture operation
23/09/2011 Change of Adviser
17/08/2011 Share Option Awards
25/07/2011 Appointment of WH Partnership re Cramlington
18/07/2011 Half Yearly Report
14/07/2011 Angel signs US consultancy agreement with BPTC
06/07/2011 Change of Accounting Reference Date
05/07/2011 Angel signs new contract with ReNeuron
05/07/2011 Contract with Angel Biotechnology Holdings plc
01/07/2011 Exercise of Options
14/06/2011 Angel's expertise assists Azellon
08/06/2011 Result of AGM
06/05/2011 Notice of AGM
04/05/2011 Angel signs contract with Pathfinder Cell Therapy
03/05/2011 Exercise of Employee Share Options
28/04/2011 Angel comments on ECJ opinion
18/04/2011 Postponement of AGM
12/04/2011 Exercise of Share Options
30/03/2011 Notice of AGM and posting of accounts
21/03/2011 Lease Agreement
16/03/2011 Appointment of Finance Director
28/02/2011 Final Results
11/02/2011 Re Agreement
02/02/2011 Additional Listing
27/01/2011 Placing
27/01/2011 Re Agreement
18/01/2011 Trading Update and Notice of Results
05/01/2011 Appointment of joint broker
23/12/2010 Angel to Further Produce ReN001 Stem Cells Batches
22/12/2010 New GMP Manufacturing Contract with Materia Medica
18/11/2010 Holding(s) in Company
16/11/2010 First Patient Treated with ReN001
09/11/2010 Business update
04/10/2010 New Materia Medica contract
16/09/2010 Issue of Shares
13/09/2010 Holdings in Company
04/08/2010 Share Option Awards
22/07/2010 Repayment of Loan
19/07/2010 Interim results for the 6 months to 30 June 2010
06/07/2010 Group Financial Controller & Company Secretary
03/06/2010 Trading Update
01/06/2010 New Materia Medica Contract
26/05/2010 Result of AGM
24/05/2010 Angel announces 3 contracts with Materia Medica
Last updated: 12:01 18/05/2012

Learn more

Contact us

for investor relations queries:
Lorna Peers
Finance Director and Company Secretary
Tel:+44 (0)131 4456077
enquiries@angelbio.com

Our services

Along with the successful production of recombinants, Angel provides development and process scale-up strategies

Our services